Samumed to announce potential disease modifying treatment of osteoarthritis at ACR 2015

November 03, 2015

SAN DIEGO -- Nov. 3, 2015 -- Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

Specifically, Samumed will present preclinical research results that demonstrate cartilage regeneration in an animal model of OA after a single intra-articular injection of SM04690 in an oral presentation. In addition, Samumed will present two posters that detail interim safety, pK, efficacy and radiographic imaging results (MRI and X-ray), respectively, from a now-completed 24-week placebo-controlled, double-blind, randomized Phase I clinical trial of SM04690 in patients with moderate to severe osteoarthritis of the knee.

"Our technology platform focuses on small molecule drugs that repair/regenerate local tissue. To date, we have advanced four compounds into clinical trials, targeting five disease areas that impact the health and quality-of-life of millions of people. We will continue to expand our pipeline, as well as share data from our programs with the scientific and medical community," said Osman Kibar, Ph.D., Chief Executive Officer and Founder of Samumed.
-end-
SAMUMED'S ACR 2015 ABSTRACTS

Poster Presentations
Sunday, Nov. 8, 2015; 8:30am -- 4:00pm
Poster #312 & #313
Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Session Title: Osteoarthritis -- Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
Session Title: Osteoarthritis -- Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Presentation
Monday, Nov. 9, 2015; 2:30pm -- 4:00pm
Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis
Session Title: Biology and Pathology of Bone and Joint: Osteoarthritis Pathogenesis

ABOUT SAMUMED, LLC

Based in San Diego, CA, Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.

Rasky Baerlein Strategic Communications

Related Osteoarthritis Articles from Brightsurf:

Major savings possible with app-based osteoarthritis treatment
Osteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in Sweden published in the research journal PLOS ONE.

New approach to treating osteoarthritis advances
Injections of a natural 'energy' molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.

Certain jobs linked to higher risk of knee osteoarthritis
Workers in jobs that typically involve heavy lifting, frequent climbing, prolonged kneeling, squatting, and standing face an increased risk of developing knee osteoarthritis.

App helps reduce osteoarthritis pain
By performing a few simple physical exercises daily, and receiving information about their disease regularly, 500 osteoarthritis patients were able to on average halve their pain in 6 months -- and improve their physical function.

Osteoarthritis can increase your risk for social isolation
In a study published in the Journal of the American Geriatrics Society, researchers examined information from the European Project on OSteoArthritis (EPOSA) study.

High rates of opioid prescriptions for osteoarthritis
Opioids work against severe pain but the risks of side effects and addiction are high.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

3D printing may help treat osteoarthritis
In a Journal of Orthopaedic Research study, scientists used 3D printing to repair bone in the joints of mini-pigs, an advance that may help to treat osteoarthritis in humans.

Finger joint enlargements may be linked to knee osteoarthritis
Heberden's nodes (HNs) are bony enlargements of the finger joints that are readily detectable in a routine physical exam and are considered hallmarks of osteoarthritis.

Read More: Osteoarthritis News and Osteoarthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.